Member Info for Bella6532

If there was a problem with the science/trial, why fundraise to progress AVA6000...?

There are thousands of trials taking place and to get patients onboard our trial looking at the very strict perameters could be a bit of a challenge. My guess is they have spent the last couplke of months preparing and recruiting plus fundraising and only now are they in a position to go full steam ahead knowing that the funds are going to be available. Chicken and egg. Economies both sides of the pond are in a mess and have suffered huge inflation...that inflation has, I'm sure hit Avacta hard too with increased costs. Yes we hear all the bla bla from our Govt leaders about inflation coming down etc but lots of prices have remained high and will continue to do so. We have many friends in the US and they are hurting, just as we are.

'According to the U.S. Bureau of Labor, the average U.S. annual salary in Q4 of 2023 was $59,384. This is up 5.4% from the same time period in 2022, when the average American was making $56,316 per year. Average weekly earnings reached $1,142, while the average American made $4,949 per month in Q4 of 2023.'

The US is expensive...very expensive, especially with regard to anything to do with medical/Pharma...

Get real guys...any investor coming in at this point is taking a risk...we are only on Phase 1...and the trial numbers are small.

Let's see what the 18th brings...

Oh..BV you are a grumpy old man aren't you. Ha ha...

Yes I would like Medicxi to be the European Speciality fund and have presented why it could be posdible...but like anything..it's not written in stone.

If it is them they wojld not only bring money to the table but they eill place one of their chaps on the board. That's where the know how and contacts needed to take Avacta and AVA6000 forward will come from.

If it's them then I think thry woll dhow their hand on 18th...if not, then I guess we will never know who it is.

With regard to some of my questions, I already know the answers as you obviously do, but some on here don't and therefore It's my simple way of bringing out healthy debate/knowledge from others and cutting through some if the dross...

Your input is very much appreciated but much prefer you when you're not quite so grumpy...😘

Companies list to basically raise funds...that's it.

Companies list on AIM because they are early stage, high risk and at the most needy for funds.

Fundraisers are a fact of life for listed companies in their early stages and it hurts short term but long term has to be your focus especially if your bought in during the Covid LFT rise.

Sorry to be so blunt guys.

Now if the 0.95 fundraise was oversubscribed then why discount so heavily now...because someone demanded it...who is the European speciality fund...??? And why is there a vote on the Rex fundraise...?

Why are we having to wait until 18th...?

GeneralOz...be careful what you wish for...he is extremely well connected...

The problem with LFTs is none of them detect Covid on day one...all a sham by Governments. Anyone with Covid often doesn't go down with symptoms for 5-7 days but infects others in the meantime. Governments simply went for cheap as chips LFTs to make people feel like it could be controlled. Look at the damage lockdowns have done and the huge Govt debts etc. You cannot protect a nation against a virus like of Covid. Even the jabs don't stop you getting it and in mzny cases have done more harm. Truth is the Government was never going to buy UK made LFTs in serious bulk quantities.

Notrex...I think if you read the AS letter in the TImes he was berating the RDR and MifID11 which hamstring investments.

Is the WithPower site AI generated...it looks like it. If they're relying on sites like this to recruit they won't get any takers...

That WithPower trial site us a crock of s...

Going it alone needs finance and a company like Medicxi to bring in licencees for the pipeline and keep the wolves away from AVA6000. They can protect our assets...so to speak

Https://www.levicept.com/management-and-board

Check out the 3rd and 4th bios...both are with Medicxi.

Medicxi is a company who could demand a buy in price of 0.50.

I really hope they are onboard because they can get us to where we really want to be...

CTSFO...Surely Dr Tap, his team and CC will have had enough ecperience between them dealing with the likes of the FCA to know what could be said/presented from the 1a trial.

No I don't think it's the FDA. I think tgey expected to find MTD around 6 /7 and having not done so together with efficacy observed, the whole emphasis has changed. Financing the 2 week trial in the US and looking to start P2 before end 2024 also in the US whilst continuing with 1a dosing isn't going to come cheap and add to that bring on another pipeline product this year. They've upped the game...they're in another gear. The potential has been seen, they now more than ever want to keep AVA6000 to themselves. They did not need to mention the fact a European speciality fund had invested...that's a set up...that's so when it comes to light who it is and how significant it might be they can't be accused of not telling us. Why also mention Nasdaq and possibly divesting DX...again they're giving us clues and they are telling us this fundraise has and will lead to a significant change of direction/focus...the question is who is going to help Avacta on their new path.

The clue IMHO is in the Eliot Forsters Sept 2023 new appoinment Press Release...and who his is now working with and has worked with for some time at other companies he's been with...

It's all posted on the Avacta site so no reason not to know what the analysists are saying..

https://avacta.com/investors/research-analyst/

and another sunday read for you...

https://*********************/notearticle/article?researchnoteid=33_79f6bd17-a6ac-465f-93fd-44fc35f8a6a2&whitelabelcompanyid=gb00byyw9g87&clearcache=false

For those desperate to know where the SP is going...

https://www.capitalaccessgroup.co.uk/research-portal?#/portal/capital-access-group

They reckon by Phase 2 it will be....

Ah ha...you've gotta read it to get the answer...

CTSFO...great posts.

I assume they have a target audience and have already sent out direct invitations with their Presentation time/place etc.

Fantastic wins for Italy and England...cracking days rugby...

Another connection.

Eliot Forster joined Immunocore Jan 2015 as CEO.

Immunocore has an ongoing collaboration with Gadeta.

Gadeta's investment sydicate includes Medicxi.

October 2023 Clade Therapeutics Announces the Acquisition of Gadeta B.V.

'Gadeta was founded in 2015 and has had collaborations with Kite Pharma, a Gilead Company and has an ongoing collaboration with Immunocore. Gadeta’s investor syndicate includes Kite Pharma, Medicxi and Utrecht Holdings. '

https://www.synconaltd.com/news-and-insights/news/clade-therapeutics-announces-the-acquisition-of-gadeta-b-v/

Also Immunocore use Consilium Strategic Communications.

Eliot Forster also joined F-Star and Charles Frummit of Medicxi used to work for F-Star

https://www.medicxi.com/team/charles-grummit

Now if Eliot Forster can't bring a company like Medicxi onboard....!!!

How many of you are going?

Bet you guys are not going to go and have it out with the BOD and spout to them what you seem happy to spout on here....

Ah! thought as much...typical...

10:28...Have I just seen 2.267m go thru???

Nursesteve...I suspect over the next few days/weeks the SP will revert back to where it was before the obvious walk down. The full funding round is not completely over yet until the vote on 18th.

Nursesteve...look at it another way...what if they were approached by the likes of Medicxi who said they would like to invest £xxm but it would need to be at a buy in price of 0.50....

Avacta want to commercialise AVA6000 themselves. They have never been in a position to do this on their own and at the same time unlock the pipeline and continue the R&D work etc. This funding round could give them a real step up and gear shift change if the European fund is the likes of Medicxi...